Everence Capital Management Inc. Raises Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Everence Capital Management Inc. increased its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 2.4% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 3,831 shares of the biopharmaceutical company’s stock after purchasing an additional 90 shares during the quarter. Everence Capital Management Inc.’s holdings in Regeneron Pharmaceuticals were worth $2,729,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently modified their holdings of the company. First National Trust Co bought a new stake in Regeneron Pharmaceuticals in the 2nd quarter worth approximately $217,000. Belpointe Asset Management LLC boosted its stake in shares of Regeneron Pharmaceuticals by 36.1% in the 2nd quarter. Belpointe Asset Management LLC now owns 1,789 shares of the biopharmaceutical company’s stock worth $1,881,000 after buying an additional 475 shares during the last quarter. TD Asset Management Inc grew its holdings in shares of Regeneron Pharmaceuticals by 30.4% in the second quarter. TD Asset Management Inc now owns 351,545 shares of the biopharmaceutical company’s stock worth $369,484,000 after acquiring an additional 82,034 shares during the period. Range Financial Group LLC increased its position in Regeneron Pharmaceuticals by 10.1% during the second quarter. Range Financial Group LLC now owns 262 shares of the biopharmaceutical company’s stock valued at $275,000 after acquiring an additional 24 shares during the last quarter. Finally, Arizona State Retirement System lifted its holdings in Regeneron Pharmaceuticals by 1.8% in the second quarter. Arizona State Retirement System now owns 31,293 shares of the biopharmaceutical company’s stock valued at $32,890,000 after acquiring an additional 550 shares during the period. 83.31% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on REGN shares. StockNews.com lowered shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Monday, November 4th. Truist Financial reduced their target price on shares of Regeneron Pharmaceuticals from $1,137.00 to $1,126.00 and set a “buy” rating for the company in a report on Friday, November 1st. Morgan Stanley dropped their price target on shares of Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating on the stock in a research note on Friday, November 1st. Leerink Partners restated a “market perform” rating and issued a $1,077.00 price objective (down from $1,175.00) on shares of Regeneron Pharmaceuticals in a research note on Tuesday, September 24th. Finally, Royal Bank of Canada decreased their target price on Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an “outperform” rating on the stock in a report on Friday, November 1st. One analyst has rated the stock with a sell rating, six have assigned a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $1,052.90.

Regeneron Pharmaceuticals Price Performance

NASDAQ REGN traded up $2.79 on Friday, reaching $717.98. The company had a trading volume of 147,813 shares, compared to its average volume of 301,415. The stock has a market capitalization of $78.90 billion, a PE ratio of 17.77, a price-to-earnings-growth ratio of 2.19 and a beta of 0.10. Regeneron Pharmaceuticals, Inc. has a 12 month low of $693.00 and a 12 month high of $1,211.20. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09. The firm’s 50 day moving average price is $772.73 and its 200 day moving average price is $976.16.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.